CD8A and cancer: As expected, Siglec15 negatively correlated with the critical steps of the cancer-immunity cycle, including the release of cancer cell antigens (Step 1), and trafficking of immune cells to tumors (Step 4) (CD8 T cell recruiting, Macrophage recruiting, Th1 cell recruiting, NK cell recruiting, DC recruiting, and TH17 recruiting) (Figure 6C).